Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px
Document › Details

Argen-X B.V.. (1/13/14). "Press Release: Argen-X Receives Two Preclinical Milestone Payments under Collaboration with Shire. Enters into Pilot Research Agreement with Boehringer Ingelheim". Breda.

Organisations Organisation Argen-X B.V.
  Today Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product SIMPLE Antibody™ discovery platform
  Product 2 drug discovery
Index term Index term  Boehringer–Argen-X: SIMPLE antibody discovery platform, 201401– collab €na pilot research agreement
Persons Person de Haard, Hans (Argen-X 201203 CSO)
  Person 2 Seymour, Albert (Shire 201401 Head of Discovery Biology + Translational Research)
     


arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing antibody discovery programs.

Initiated in February 2012, the collaboration is focused on creating human therapeutic antibodies against complex targets implicated in severe, rare genetic diseases. Shire has an option to license the most promising antibody leads for further development and commercialization worldwide, in return for fee, milestone and royalty payments.

"Yet again the functional diversity of SIMPLE Antibodies™ has enabled our scientists to set a precedent in validating highly complex targets both in vitro and in vivo and identifying antibody leads with exciting therapeutic potential," said Hans de Haard, PhD, Chief Scientific Officer of arGEN-X. "We value our collaboration with Shire very highly and continue to make excellent progress through the outstanding joint efforts of our teams."

"We are very impressed by the productivity and consistent success of our therapeutic antibody collaboration with arGEN-X," said Albert Seymour, Head of Discovery Biology and Translational Research at Shire.

arGEN-X today also announced the initiation of a new pilot research agreement with Boehringer Ingelheim. No further details are being disclosed at this stage.


About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

http://www.argen-x.com

   
Record changed: 2016-01-10

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Argen-X (Argenx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top